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attending a peri-urban clinic supported by MJAP and funded
by PEPFAR.
Methods: From November 2005 to November 2007, con-
secutive treatment naive patients initiating ART at the clinic
were enrolled. Clinical information is collected every month
and CD4+ count measured every 6 months. This analysis
includes patients who had completed at least 10 months
of follow up. Response to therapy was assessed by changes
in CD4 cell counts, weight, and occurrence of opportunis-
tic infections. WHO staging, adherence levels and patient
retention were also assessed.
Results: During the study period, 694 of 2686 in care,
started ART; the mean age was 34 years, 76% were female,
40% were in WHO stage 3&4, mean body weight was 54.5 kg
(SD = 9.5) and median CD4 cell count 118/mm3.
Outcomes could not be assessed in 19% of 694 (43 died,
50 were lost to follow up, 36 were transferred out to other
health centers).
The mean increase in CD4+ count at 6 months was
135/mm3 and median body weight increase was 5.0 kg. 68%
of 565 active gained weight. ART initiation reduced inci-
dence of opportunistic infections(OR:3.35, P = 0.003;). Over
98% of patients had >95% adherence. Patients with WHO
stage 1&2 were twice more likely to be active compared
to those with WHO stage 3&4.(OR:1.84, P = 0.002).
Conclusion: HAART programs can be feasibly imple-
mented at lower health facilities providing general
outpatient care with satisfactory clinical and immunological
outcomes and patient retention rates.
doi:10.1016/j.ijid.2008.05.505
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Automated drug resistance predictions, based on muta-
tion analysis, is increasingly important in virology. Unfortu-
nately most mutation analysis systems are closed systems,
leaving the user unaware on which mutation rules are ﬁred
and what part of data caused them to ﬁre. Based on curves
obtained after direct sequencing, mutants can easily be
spotted, identiﬁed and inventoried.
We present an integrated open Expert Rule System (ERS)
build into the BioNumerics® software that allows researchers
to create, adapt and (re)evaluate e.g. drug resistance rules
(double loop learning). The ERS consists of 5 major steps:
- data input directly from the BioNumerics® database or
from external sources (e.g. RT-sequences)
- data conversion for the data processing (e.g. AA-
conversion and mutation detection against a consensus)
- decision rules application, yielding a statistics report on
some or all rules (e.g. rules for all NRTI drugs)
- ERS interpretation, yielding resistance predictions for
each drug with anticipation scores based on fuzzy logic
- reporting in a written format, a database format, or pub-
lication on a website
The tool can be shown as an interactive GUI or run for
background HT batch analysis. The ERS was tested with pub-
licly available HIV data and drug resistance algorithms, but is
‘open’ for custom rule development. Discordances between
different algorithms can be easily monitored and examined.
This framework is not restricted to HIV, but can be used for
e.g. HBV as well.
doi:10.1016/j.ijid.2008.05.506
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In HIV infection, a long asymptomatic period precedes
disease development. However, viral-host interaction is
dynamic. Mathematical models have been crucial to rule
out the concept of viral latency. The present study aims
at evaluating viral-host interactions in HIV infection, inves-
tigating the impact of initial antiretroviral therapy (ART)
(mono therapy vs. double therapy vs. highly active ther-
apy) in the course of disease. Using a database with at
least six sequential CD4+ cell counts and HIV viral load
assessments of 1391 patients under follow-up in Sa˜o Paulo,
Brazil, we classiﬁed patients according to a linear approx-
imation model of plasma viral loads and CD4+ cell counts
into favourable and unfavourable outcomes. We validated
the linear approach according to two criteria, based on 2
and Q 2 (
2/degrees of freedom). Association between out-
comes and the initial therapy was sought after analyzing
the viral load and CD4+ cell counts slopes. No particu-
lar initial regimen was shown associated with plasma viral
undetectability during follow-up. Only 20% of patients with
persistent vireamia presented a beneﬁcial effect of ART.
Unfavourable outcomes were associated with most patients
who resumed vireamia transiently or at the end of follow-
up. For most patients with intermittent vireamia ending
with undetectable or detectable viral loads, results indi-
cated favourable and unfavourable outcomes, respectively,
regardless of the initial ART regimen. Distinct outcomes
occurred among patients with oscillatory viral loads: most
of those who started therapy with two or three drugs
had a favourable outcome, in contrast to those started on
monotherapy. We conclude that mathematical tools have
demonstrated that the initially prescribed ART was not asso-
ciated with the long-term response to therapy for most
analysed patients. Favourable outcomes can be associated
to reinforcement of adherence or changes in ART regimens
during follow-up. Emergence and positive selection of drug-
resistant viral strains might be hypothesized as implicated
in unfavourable outcomes.
doi:10.1016/j.ijid.2008.05.507
